Abcam PLC (NASDAQ:ABCZY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Friday, July 28th.
According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “
Abcam PLC (NASDAQ ABCZY) opened at 14.09 on Friday. The company’s 50 day moving average price is $13.19 and its 200 day moving average price is $11.82. Abcam PLC has a 12 month low of $9.13 and a 12 month high of $14.13. The firm has a market capitalization of $2.85 billion and a P/E ratio of 53.57.
TRADEMARK VIOLATION WARNING: “Abcam PLC (NASDAQ:ABCZY) Cut to “Sell” at Zacks Investment Research” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/08/10/abcam-plc-nasdaqabczy-cut-to-sell-at-zacks-investment-research-updated.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abcam PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam PLC and related companies with MarketBeat.com's FREE daily email newsletter.